NTRK fusion solid tumours
Oncology · 2021–2022
2decisions
1medicine
2carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| larotrectinib Targeted treatment of NTRK fusion solid tumours that are unresectable locally advanced, metastatic, or locally advanced and would otherwise require disfiguring… | Mar 2022 | Recommended with restriction | input received |
| larotrectinib Locally advanced or metastatic solid tumours harbouring NTRK gene fusion in paediatric and adult patients (high and low fusion frequency subtypes), including… | Nov 2021 | Deferred | input received |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.